{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:28:22Z","timestamp":1761128902003,"version":"build-2065373602"},"reference-count":64,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.revmed.2011.02.007","type":"journal-article","created":{"date-parts":[[2011,3,8]],"date-time":"2011-03-08T01:48:48Z","timestamp":1299548928000},"page":"751-757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Traitement de la goutte"],"prefix":"10.1016","volume":"32","author":[{"given":"J.-J.","family":"Dubost","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Soubrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2011.02.007_bib0005","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","article-title":"Gout","volume":"375","author":"Richette","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2011.02.007_bib0010","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/rheumatology\/kep332","article-title":"Prescription and comorbidity screening following consultation for acute gout in primary care","volume":"49","author":"Roddy","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.revmed.2011.02.007_bib0015","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1749-6632.2009.04674.x","article-title":"Colchicine revisited","volume":"1173","author":"Bhat","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.revmed.2011.02.007_bib0020","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1445-5994.1987.tb01232.x","article-title":"Does colchicine work? The results of the first controlled study in acute gout","volume":"17","author":"Ahern","year":"1987","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.revmed.2011.02.007_bib0025","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006190","article-title":"Colchicine for acute gout (Review)","author":"Schlesinger","year":"2006","journal-title":"Cochrane Database Sys Rev"},{"key":"10.1016\/j.revmed.2011.02.007_bib0030","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High-vs low-dosing of oral colchicine for early acute gout flare: Twenty-four hour outcome results of the first randomized, placebo-controlled, dose comparison colchicine trial","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2011.02.007_bib0035","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.revmed.2011.02.007_bib0040","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2011.02.007_bib0045","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.revmed.2009.03.013","article-title":"Risque d\u2019intoxication \u00e0 la colchicine chez les personnes ag\u00e9es et moyens de prevention: \u00e0 propos de quatre observations","volume":"30","author":"Le Bellec","year":"2009","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2011.02.007_bib0050","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.semarthrit.2008.08.006","article-title":"Colchicine Update 2008","volume":"38","author":"Terkeltaub","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2011.02.007_bib0055","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/01.SMJ.0000163315.02563.B2","article-title":"Two probable cases of serious drug interaction between clarithromycin and colchicine","volume":"98","author":"Cheng","year":"2005","journal-title":"South Med J"},{"key":"10.1016\/j.revmed.2011.02.007_bib0060","first-page":"S414","article-title":"New dosing guidelines for colchicine to avoid toxicity when used with Ca2+ Channel Blockers: The potent P-Gp\/CYP3\u00a0inhibitor verapamil increases maximal concentration of single-dose colchicine by 30\u00a0% and exposure by \u223c 100\u00a0% in healthy subjects","volume":"60","author":"Terkeltaub","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2011.02.007_bib0065","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/rheumatology\/kel071","article-title":"Effectiveness of interventions for the treatment of acute and prevention of recurrent gout\u2013a systematic review","volume":"45","author":"Sutaria","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.revmed.2011.02.007_bib0070","first-page":"CD005521","article-title":"Systemic corticosteroids for acute gout (Review)","author":"Janssens","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.revmed.2011.02.007_bib0075","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.annemergmed.2006.11.014","article-title":"Comparison of oral prenisolone\/paracetamol and oral indomethacin\/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial","volume":"49","author":"Man","year":"2007","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.revmed.2011.02.007_bib0080","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0140-6736(08)60799-0","article-title":"Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial","volume":"371","author":"Janssens","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2011.02.007_bib0085","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(08)61548-2","article-title":"Should prednisolone be first-line therapy for acute gout?","volume":"372","author":"Richette","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2011.02.007_bib0090","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00003495-200868040-00002","article-title":"Overview of the management of acute gout and the role of adrenocorticotropic hormone","volume":"68","author":"Schlesinger","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.revmed.2011.02.007_bib0095","first-page":"2285","article-title":"Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide","volume":"26","author":"Fern\u00e1ndez","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2011.02.007_bib0100","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00296-005-0617-7","article-title":"Successful treatment of chronic tophaceous gout with infliximab (Remicade)","volume":"26","author":"Fiehn","year":"2006","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.revmed.2011.02.007_bib0105","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/ard.2003.015743","article-title":"Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumor necrosis factor \u03b1 as a new therapeutic option","volume":"63","author":"Tausche","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2011.02.007_bib0110","doi-asserted-by":"crossref","unstructured":"J\u00e9ru I, Amselem S. Inflammasome et interleukine 1. Rev Med Interne doi:10.1016\/j.revmed 2010.02.013 (sous presse).","DOI":"10.1016\/j.revmed.2010.02.013"},{"key":"10.1016\/j.revmed.2011.02.007_bib0115","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1002\/art.22938","article-title":"The role of interleukin-1\u00a0and the inflammasome in gout: implications for therapy","volume":"56","author":"Pope","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2011.02.007_bib0120","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A pilot study of IL-1\u00a0inhibition by anakinra in acute gout","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.revmed.2011.02.007_bib0125","doi-asserted-by":"crossref","first-page":"16983","DOI":"10.1136\/ard.2007.073759","article-title":"Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra","volume":"66","author":"McGonagle","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"61","key":"10.1016\/j.revmed.2011.02.007_bib0130","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/art.24694","article-title":"Case of anakinra as a steroid-sparing agent for gout inflammation","volume":"15","author":"Gratton","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2011.02.007_bib0135","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/art.23119","article-title":"Successful treatment of resistant pseudogout with anakinra","volume":"58","author":"McGonagle","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2011.02.007_bib0140","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/ard.2009.108936","article-title":"The interleukin 1\u00a0inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study","volume":"68","author":"Terkeltaub","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2011.02.007_bib0145","first-page":"S410","article-title":"Placebo-controlled study of rilonacept for gout flare prophylaxis during initiation of urate-lowering therapy","volume":"60","author":"Schumacher","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2011.02.007_bib0150","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis. Result of a multicenter, phase II, dose-ranging study","volume":"62","author":"So","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2011.02.007_bib0155","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/01.rhu.0000249864.95389.cf","article-title":"Response to application of ice may help differentiate between gouty arthritis and other inflammatory arthritides","volume":"12","author":"Schlesinger","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.revmed.2011.02.007_bib0160","first-page":"S762","article-title":"Drinking water can reduce the risk of recurrent gout attacks","volume":"60","author":"Neogi","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2011.02.007_bib0165","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/rheumatology\/keg297","article-title":"Concomitant septic and gouty arthritis-an analysis of 30\u00a0cases","volume":"42","author":"Yu","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.revmed.2011.02.007_bib0170","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2011.02.007_bib0175","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2011.02.007_bib0180","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2011.02.007_bib0185","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1525-139X.2007.00270.x","article-title":"Allopurinol dosing in renal impairment: Walking the tightrope between adequate urate lowering and adverse events","volume":"20","author":"Dalbeth","year":"2007","journal-title":"Semin Dial"},{"key":"10.1016\/j.revmed.2011.02.007_bib0190","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.revmed.2011.02.007_bib0195","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11926-009-0019-z","article-title":"A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout","volume":"11","author":"Chao","year":"2009","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.revmed.2011.02.007_bib0200","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/ard.60.10.981","article-title":"Relation between adverse events associated with allopurinol and renal function in patients with gout","volume":"60","author":"V\u00e1zquez-Mellado","year":"2001","journal-title":"Ann Rheum Dis"},{"issue":"102","key":"10.1016\/j.revmed.2011.02.007_bib0205","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801\u00a0allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"15","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.revmed.2011.02.007_bib0210","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","article-title":"Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment","volume":"63","author":"Stamp","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2011.02.007_bib0215","doi-asserted-by":"crossref","first-page":"ii15","DOI":"10.1093\/rheumatology\/kep088","article-title":"Febuxostat: a new treatment for hyperuric\u00e6mia in gout","volume":"48","author":"Edwards","year":"2009","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.revmed.2011.02.007_bib0220","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"6","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.revmed.2011.02.007_bib0225","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","article-title":"A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?","volume":"31","author":"Lee","year":"2008","journal-title":"Drug Saf"},{"key":"10.1016\/j.revmed.2011.02.007_bib0230","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","article-title":"Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2011.02.007_bib0235","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","article-title":"A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600mg\/day versus benzbromarone 100-200mg\/day in patients with gout","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2011.02.007_bib0240","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3904\/kjim.2006.21.2.89","article-title":"Effect of fenofibrate in combination with urate lowering agents in patients with gout","volume":"21","author":"Lee","year":"2006","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.revmed.2011.02.007_bib0245","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/ard.62.6.572","article-title":"Effects of combination treatment using anti-hyperuric\u00e6mic agents with fenofibrate and\/or losartan on uric acid metabolism","volume":"62","author":"Takahashi","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2011.02.007_bib0250","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10067-005-0043-y","article-title":"Rasburicase treatment in severe tophaceous gout: a novel therapeutic option","volume":"25","author":"Moolenburgh","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.revmed.2011.02.007_bib0255","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/ndt\/gfh629","article-title":"Urate oxidase (rasburicase) for treatment of severe tophaceous gout","volume":"20","author":"Vogt","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.revmed.2011.02.007_bib0260","first-page":"658","article-title":"Urate oxidase (rasburicase) for treatment of severe acute gout: a case report","volume":"27","author":"Wipfler-Freibmuth","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2011.02.007_bib0265","first-page":"2093","article-title":"Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study","volume":"34","author":"Richette","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2011.02.007_bib0270","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.addr.2007.06.011","article-title":"PEG-uricase in the management of treatment-resistant gout and hyperuricemia","volume":"60","author":"Sherman","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.revmed.2011.02.007_bib0275","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1002\/art.23810","article-title":"Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2011.02.007_bib0280","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","article-title":"Purine-rich foods, dairy and protein intake, and the risk of gout in men","volume":"350","author":"Choi","year":"2004","journal-title":"N Eng J Med"},{"key":"10.1016\/j.revmed.2011.02.007_bib0285","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/art.20761","article-title":"Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey","volume":"52","author":"Choi","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2011.02.007_bib0290","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(04)16000-5","article-title":"Alcohol intake and risk of incident gout in men: a prospective study","volume":"363","author":"Choi","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2011.02.007_bib0295","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/bmj.39449.819271.BE","article-title":"Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study","volume":"336","author":"Choi","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.revmed.2011.02.007_bib0300","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/art.22712","article-title":"Coffee consumption and risk of incident gout in men: a prospective study","volume":"56","author":"Choi","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2011.02.007_bib0305","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/art.22762","article-title":"Coffee, tea, and caffeine consumption and serum uric acid level: the Third National Health and Nutrition Examination Survey","volume":"57","author":"Choi","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"169","key":"10.1016\/j.revmed.2011.02.007_bib0310","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1001\/archinternmed.2008.606","article-title":"Vitamin C intake and the risk of gout in men: a prospective study","volume":"9","author":"Choi","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.revmed.2011.02.007_bib0315","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/art.21105","article-title":"The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial","volume":"52","author":"Huang","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2011.02.007_bib0320","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/acr.20065","article-title":"Hyperuricemia and coronary heart disease: a systematic review and meta-analysis","volume":"62","author":"Kim","year":"2010","journal-title":"Arthritis Care Res"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866311000713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866311000713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:28:55Z","timestamp":1759336135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866311000713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":64,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0248866311000713"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2011.02.007","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Traitement de la goutte","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2011.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Soci\u00e9t\u00e9 nationale fran\u00e7aise de m\u00e9decine interne (SNFMI). Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}